Prudential PLC Buys 1,835 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Prudential PLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,672 shares of the company's stock after purchasing an additional 1,835 shares during the quarter. Prudential PLC owned 0.06% of IDEXX Laboratories worth $21,777,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Cranbrook Wealth Management LLC raised its stake in IDEXX Laboratories by 7.0% in the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after acquiring an additional 25 shares during the period. Perigon Wealth Management LLC raised its holdings in shares of IDEXX Laboratories by 1.8% in the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after acquiring an additional 26 shares in the last quarter. Summit Trail Advisors LLC raised its stake in IDEXX Laboratories by 3.3% in the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after purchasing an additional 26 shares in the last quarter. IFP Advisors Inc lifted its position in IDEXX Laboratories by 3.6% during the fourth quarter. IFP Advisors Inc now owns 903 shares of the company's stock valued at $373,000 after purchasing an additional 31 shares during the last quarter. Finally, Cape Cod Five Cents Savings Bank grew its stake in IDEXX Laboratories by 0.5% in the 3rd quarter. Cape Cod Five Cents Savings Bank now owns 6,344 shares of the company's stock worth $3,091,000 after buying an additional 32 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Remove Ads

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IDXX. Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Finally, Morgan Stanley decreased their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Stock Up 1.7 %

Shares of IDXX stock traded up $6.18 during trading hours on Wednesday, hitting $367.22. 562,559 shares of the company's stock traded hands, compared to its average volume of 602,170. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a market cap of $29.76 billion, a price-to-earnings ratio of 34.31, a PEG ratio of 3.41 and a beta of 1.50. The stock's fifty day simple moving average is $432.29 and its two-hundred day simple moving average is $436.78. IDEXX Laboratories, Inc. has a 12-month low of $353.94 and a 12-month high of $548.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.